VYNE Therapeutics
VYNE
49 hedge funds and large institutions have $579M invested in VYNE Therapeutics in 2018 Q1 according to their latest regulatory filings, with 49 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.98% more ownership
Funds ownership: 0% → 0.98% (+0.98%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$136M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$69.1M |
| 3 |
PA
Perceptive Advisors
New York
|
+$54M |
| 4 |
VP
venBio Partners
San Francisco,
California
|
+$49.4M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$46M |
Top Sellers
VYNE Hedge Fund Activity: Q1 2018 in Review
49 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q1 2018, worth a combined $579M.
Buyers outnumbered sellers: 49 funds opened new VYNE positions and 0 closed out — a net gain of 49 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $136M.
- 49 institutional investors held VYNE Therapeutics (VYNE) as of Q1 2018, up from 0 in Q4 2017.
- Funds reported $579M of VYNE Therapeutics stock for Q1 2018.
- 49 funds opened new VYNE Therapeutics positions in Q1 2018 and 0 closed out, a net change of +49 holders.
- The largest VYNE Therapeutics buyer in Q1 2018 was Vivo Capital, an estimated $136M added.
Based on aggregated 13F filings for Q1 2018.